EyePoint Pharmaceuticals, Inc.
EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.42
Price+1.39%
$0.17
1Y
Price
Market Cap
$1.041b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-12104.3%
EBITDA Margin-12188.5%
Net Profit Margin-11716.4%
Free Cash Flow Margin-12104.3%
EBITDA Margin-12188.5%
Net Profit Margin-11716.4%
Free Cash Flow MarginRevenue
$7.615m
-75.7%
1y CAGR-36.4%
3y CAGR-24.5%
5y CAGREarnings
-$271.599m
-17.1%
1y CAGR-59.7%
3y CAGR-37.1%
5y CAGREPS
-$3.50
-10.4%
1y CAGR-24.8%
3y CAGR-10.2%
5y CAGRBook Value
$230.472m
$288.217m
Assets$57.745m
Liabilities$22.314m
DebtDebt to Assets
7.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$271.540m
-11.6%
1y CAGR-2700.1%
3y CAGR-2000.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company